Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani, Kamran Mansouri, Mohammad Sajad Emami Aleagha, Narges Moasefi, Niloofar Yavari, Seyed Kazem Shakouri, Sara Notararigo, Ali Shojaeian, Flemming Pociot, Reza Yarani

Abstract

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

OriginalsprogEngelsk
Artikelnummer865782
TidsskriftFrontiers in Immunology
Vol/bind13
Sider (fra-til)865782
ISSN1664-3224
DOI
StatusUdgivet - 8 apr. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Extracellular Vesicle Therapy for Type 1 Diabetes'. Sammen danner de et unikt fingeraftryk.

Citationsformater